Tim A. Ahles, PhD, on Neurocognitive Late Effects
2016 Cancer Survivorship SymposiumTim A. Ahles, PhD, of Memorial Sloan Kettering Cancer Center, discusses “chemobrain” and what can be done to help patients cope with this symptom.
Tim A. Ahles, PhD, of Memorial Sloan Kettering Cancer Center, discusses “chemobrain” and what can be done to help patients cope with this symptom.
Erin Elizabeth Hahn, PhD, MPH, of Kaiser Permanente Southern California, discusses the use of recommended post-treatment services for adolescent and young adult Hodgkin lymphoma survivors (Abstract 107).
Kerri M. Winters-Stone, PhD, of Oregon Health and Science University, discusses the results of her study, which showed that, years after treatment, nearly half of women cancer survivors still have symptoms of chemotherapy-induced peripheral neuropathy. The findings may inform rehabilitative programs to prevent falls and injuries (Abstract 130).
Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, summarizes the main take-home messages of the conference.
Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute, discusses these side effects and some practical approaches to managing them with educational, medical, behavioral, and lifestyle interventions.
Craig E. Pollack, MD, of Johns Hopkins University, discusses a study of survivorship care plans for this special population (Abstract 1).